VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
EDAP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
EDAPEdap Tms S.a.
$4.75$178M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

EDAP logoEdap Tms S.a.(EDAP)Earnings, Financials & Key Ratios

EDAP•NASDAQ
$4.75
Price updated Jul 2, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryImaging, radiation, and oncology devices
AboutEDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.Show more
  • Revenue$71M+10.3%
  • EBITDA-$22M-21.2%
  • Net Income-$29M-54.3%
  • EPS (Diluted)-0.78-52.9%
  • Gross Margin42.54%+2.7%
  • EBITDA Margin-30.79%-9.9%
  • Operating Margin-35.63%-11.3%
  • Net Margin-41.47%-39.8%
  • ROE-97.29%-150.2%

EDAP Price & Volume

Edap Tms S.a. (EDAP) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Challenge Capital Structure Stability

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Rapid liquidity depletion

Key Thesis Takeaways

  • EDAP faces a precarious fundamental outlook as it struggles to convert revenue growth into sustainable profitability, evidenced by a 2026Q1 operating margin of -41.4%.
  • While the company is aggressively pursuing market expansion for its Focal One platform, the lack of operating leverage and significant cash burn threaten long-term viability.
  • Investors should monitor the company's ability to stabilize its balance sheet, which has seen shareholders' equity plummet from $56.9M in 2023Q4 to $10.1M in 2026Q1.

Verdict Logic

the company's inability to achieve positive free cash flow, highlighted by a -20.9% FCF margin in 2026Q1, suggests an unsustainable reliance on existing cash reserves to fund ongoing operations.

EDAP Growth Metrics

Edap Tms S.a. (EDAP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years8.17%
5 Years11.17%
3 Years8.68%
TTM14.72%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-39.35%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-42.59%

Return on Capital

10 Years-13.17%
5 Years-25.96%
3 Years-40.06%
Last Year-55.95%

EDAP Recent Earnings

Edap Tms S.a. (EDAP) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.24-9.1%
$0.22
Rev
$18M+7.4%
$17M
Q2 2026
Mar 25, 2026
Metric
Actual
Est
EPS
$0.25-56.3%
$0.16
Rev
$22M+2.6%
$21M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.15+42.3%
$0.26
Rev
$16M-23.6%
$21M
Q3 2025
Aug 28, 2025
Metric
Actual
Est
EPS
$0.17+5.6%
$0.18
Rev
$19M+29.5%
$15M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.24vs $0.22-9.1%
$18Mvs $17M+7.4%
Q2 2026Mar 25, 2026
$0.25vs $0.16-56.3%
$22Mvs $21M+2.6%
Q4 2025Nov 6, 2025
$0.15vs $0.26+42.3%
$16Mvs $21M-23.6%
Q3 2025Aug 28, 2025
$0.17vs $0.18+5.6%
$19Mvs $15M+29.5%
Based on last 12 quarters of dataView full earnings history →

Peers Comparison

Key metrics vs top competitors for Edap Tms S.a. (EDAP)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
EDAP logoEDAPEdap Tms S.a.Current
$4.76$178.23M-6.1010.34%-41.47%-97.29%—
AEYE logoAEYEAudioEye, Inc.
$7.24$90.45M-28.9614.52%-9.05%-70.95%—
ISRG logoISRGIntuitive Surgical, Inc.
$432.83$153.29B55.0020.51%28.15%16.89%—
NVCR logoNVCRNovoCure Limited
$17.32$1.97B-14.208.28%-25.66%-50.82%—
IRTC logoIRTCiRhythm Technologies, Inc.
$126.03$4.14B-90.6726.24%-3.53%-20.6%—
GKOS logoGKOSGlaukos Corporation
$148.70$8.7B-45.3432.33%-34.34%-26.46%—

Compare EDAP vs Peers

Edap Tms S.a. (EDAP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AEYE

Most directly comparable listed peer for EDAP.

Scale Benchmark

vs ISRG

Larger-name benchmark to compare EDAP against a more recognizable public peer.

Peer Set

Compare Top 5

vs AEYE, ISRG, NVCR, IRTC

EDAP SEC Filings & Documents

Edap Tms S.a. (EDAP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Apr 2, 2026·SEC

Material company update

Mar 25, 2026·SEC

10-K Annual Reports

1
FY 2026

Mar 25, 2026·SEC

10-Q Quarterly Reports

1
FY 2026

May 7, 2026·SEC

Get notified when EDAP posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

EDAP Frequently Asked Questions

Edap Tms S.a. (EDAP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Edap Tms S.a.'s revenue?

Edap Tms S.a. (EDAP) reported $72.0M in revenue for fiscal year 2025. This represents a 120% increase from $32.7M in 1997.

How fast is Edap Tms S.a. growing?

Edap Tms S.a. (EDAP) grew revenue by 10.3% over the past year. This is steady growth.

Is EDAP profitable?

Edap Tms S.a. (EDAP) reported a net loss of $30.0M for fiscal year 2025.

Dividend & Returns
What is EDAP's return on equity?

Edap Tms S.a. (EDAP) has a return on equity (ROE) of -97.3%. Negative ROE indicates the company is unprofitable.

What is Edap Tms S.a.'s free cash flow?

Edap Tms S.a. (EDAP) had negative free cash flow of $19.3M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in EDAP back in 1997?

Total return calculator · dividends reinvested · 29+ years of data

See returns →